Antiplatelet therapy in cardiovascular disease

Postgraduate Medical Journal

Volumn 80, Issue 941, 2004, Pages 155-164

  Behan, M W H ^a   Storey, R F ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; BARBOURIN; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PROSTAGLANDIN SYNTHASE; THIENO[3,2 C]PYRIDINE DERIVATIVE; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; META ANALYSIS; NEUTROPENIA; PROPHYLAXIS; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ASPIRIN; CARDIOVASCULAR DISEASES; DIPYRIDAMOLE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES;

EID: 1642345260     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2003.007062     Document Type: Review

References (68)

1. Sans S, Kesteloo H, Kromhout D. The burden of cardiovascular diseases on mortality in Europe: Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-48.
2. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361-6.
3. Ross R. Atherosclerosis as an inflammatory disease. N Engl J Med 1999;340:115-26.
4. Eisert WG. How to get from antiplatelet to antithrombotic treatment. Am J Ther 2001;8:443-9.
5. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9.
6. Heptinstoll S. The importance of platelet aggregation in coronary artery disease. British Journal of Cardiology 2000;7(suppl):S27-30.
7. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders, 1997:1184-288.
8. Fuster V. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
9. Fernandez-Ortiz A, Badimon J, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
10. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
11. Willerson JT, Cohen LS, Maseri A. Pathophysiology and clinical recognition. In: Willerson JT, Cohen LS, eds. Cardiovascular medicine. New York: Churchill Livingstone, 1995.
12. Clemetson KJ. Platelet activation: signal transduction via membrane receptors. Thromb Haemost 1995;74:149-55.
13. Robbie LA, Booth NA, Croll AM, et al. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993;70:301-6.
14. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator type-1 from platelets. Thromb Haemost 1993;72:413-21.
15. Pawar D, Shahani S, Maroli S. Aspirin - the novel antiplatelet drug. Hong Kang Medical Journal 1998;4:415-8.
16. Singer R. Acetyl salicylic acid, probable cause for secondary, past tonsillectomy haemorrhage. Preliminary report. Arch Otolaryngol 1945;42:19.
17. Patrano C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
18. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
19. Buerke M, Pittroff W, Meyer J, et al. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995;130:465-72.
20. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Society. N Engl J Med 1983;309:396-403.
21. Cairns JA, Gent M, Singer J, et al. Aspirin, sulphinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.
22. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
23. Research Group on Instability in Coronary Artery Disease in Southeast Sweden (RISC). Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk of myocardial infarction, occurrence of severe angina and the need for revascularisation. J Am Coll Cardiol 1991;18:1587-93.
24. Manson JE, Grobbee DE, Stamfer MJ, et al. Aspirin in the primary prevention of angina pectoris in a randomised trial of United States physicians. Am J Med 1990;89:772-6.
25. Ridker PM, Manson JE, Gazianio JM, et al. Low-dose aspirin therapy for chronic stable angina: a randomised placebo controlled trial. Ann Intern Med 1991;114:835-9.
26. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5.
27. Fitzgerald DJ, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.
28. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
29. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-26.
30. Derry S, Kong Loke Y. Risk of gastrointestinal haemorrhage with long-term use of aspirin: met-analysis. BMJ 2000;321:1183-7.
31. Savi P, Nurden P, Levy-Toledano S, et al. Clopidogrel: a review of its mechanism of action. Platelets 1998;9:251-5.
32. Noble S, Goa KL. Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging 1996;8:214-32.
33. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
34. Scheming A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
35. Bertrand M, Rupprecht HJ, Urban P. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
36. CURE Study Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
37. Mehto SR, Yusuf S, Peters RJG, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
38. Steinhubl SR, Berger PB, Tift Mann III J, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411-20.
39. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13:407-13.
40. 12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002;88:488-94.
41. Persantin-Aspirin Reinfarcrion Study (PARIS) Research Group. The persantin-aspirin reinfarction study. Circulation 1980;62:V85-8.
42. Diener H, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. J Neurol Sci 1996;143:1-13.
43. Shattil SJ. Function and regulation of the B3 integrins in haemostasis and vascular biology. Thromb Haemost 1995;74:149-55.
44. Clemetson KJ. Platelet activation: signal transduction via membrane receptors. Thromb Haemost 1995;74:111-16.
45. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86:427-43.
46. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 2000;36:2028-35.
47. Scarborough RM. Development of eptifibatide. Am Heart J 1999;138:1093-104.
48. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
49. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997;336:1689-96.
50. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
51. Topol EJ, Mark DB, Lincoff AM, et al. For the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet 1999;354:2019-24.
52. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
53. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287:618-21.
54. Topol EJ, Moliterno DJ, Herrmann HC, et al. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abdximab, for the prevention of ischaemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
55. Hobbach H-P, Schuster P. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Z Kardiol 2003;92:213-8.
56. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischaemic Syndrome Management Study Investigators. N Engl J Med 1998;338:1498-505.
57. Platelet Receptor in Ischaemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
58. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
59. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.
60. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
61. Cannon CP, Weintraub WS, Demopaulos L, et al. The TACTICS-Thrombolysis in Myocardial Infarction. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
62. Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
63. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA organization and randomized trial (RAPPORT). Circulation 1998;98:734-41.
64. Stone GW, Grines CL, Cox DA, et al. For the Controlled Abdximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
65. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI 14) trial. The TIMI 14 Investigators. Circulation 1999;99:2720-32.
66. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
67. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orofiban in patients with unstable coronary syndromes (OPUS-TIMI 16). Circulation 2000;102:149-56.
68. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischaemic heart events past-acute coronary syndromes. Lancet 2000;355:337-45.